bone growth

CHICAGO (MedPage Today) -- Spine surgery patients who got a bone growth stimulating agent as part of a clinical trial were three to five times more likely to develop cancer two to three years after being implanted with the product, according to a new analysis reported here.

Stryker Corp.'s biotech division and four current and former executives have been indicted on federal fraud charges related to their marketing of two bone-growth products.

(Thomas Jefferson University) A recent United States Army study found that excessive bone growth, also known as heterotopic ossificiation (HO), affects up to 70 percent of soldiers who are severely wounded during combat.

The excessive bone forms within muscles and other tissues causing severe pain, reduced mobility and even local paralysis if untreated.

A new study by Thomas Jefferson University researchers found a way to prevent HO in animal models by shutting the process off in its early stages.

CHICAGO (AP) -- A bone growth agent used in thousands of spinal fusion surgeries for neck pain has been linked to complications and higher cost, according to the first nationwide study of the product.

Safety questions arose last year about the protein product, BMP, when used in fusion surgeries in the neck region, a use not approved by federal regulators....